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Mycobacterium bovis bacillus Calmette-Guérin (BCG) is currently the only vaccine
available for preventing tuberculosis (TB), however, BCG has varying success
in preventing pulmonary TB. In this study, a recombinant BCG (rBCG::Ag85A)
strain overexpressing the immunodominant Ag85A antigen was constructed, and
its immunogenicity and protective efficacy were evaluated. Our results indicated
that the Ag85A protein was successfully overexpressed in rBCG::Ag85A, and the
Ag85A peptide–MHC complexes on draining lymph node dendritic cells of C57BL/6
mice infected with rBCG::Ag85A were detectable 4 h post-infection. The C57BL/6
mice infected with this strain had stronger antigen-specific interferon-gamma (IFN-γ)
responses and higher antibody titers than those immunized with BCG, and the protective
experiments showed that rBCG::Ag85A can enhance protection againstMycobacterium
tuberculosis (M. tuberculosis) H37Rv infection compared to the BCG vaccine alone. Our
results demonstrate the potential of rBCG::Ag85A as a candidate vaccine against TB.
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INTRODUCTION
Tuberculosis (TB) is caused by the intracellular pathogen Mycobacterium tuberculosis is (M.
tuberculosis), and is responsible for about 2 million deaths each year and an estimated 9 million
new cases annually (Rappuoli, 2014). Despite a TB vaccine being available for more than 90 years,
TB remains a major global health issue (Rappuoli, 2014). The bacillus Calmette-Guérin (BCG)
vaccine is effective against miliary and meningeal TB in children, but provides variable protection
against pulmonary TB in adults (Andersen and Doherty, 2005). Therefore, alternative vaccines or
supplements to the BCG vaccine are needed.
However, the development of novel vaccines outperforming BCG is difficult. Recently, 12 new
TB vaccines have entered clinical trials, which are focused on two goals: (1) improve the existing
vaccine by replacing BCGwith attenuated bacterial strains derived fromBCG orM. tuberculosis, for
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example, VPM1002 (rBCG1ureC::hly) was an attenuated strain,
which was safe and immunogenic for B-cell and T-cell responses,
and it is the most advanced recombinant vaccine in clinical
trial (Grode et al., 2013), while rBCG30 strain was obtained by
engineering BCG to overexpress Ag85B to induce better immune
response (Gillis et al., 2014), (2) improve the TB vaccine by
boosting BCG induced immunity using protein-based vaccines
delivered in the presence of adjuvants or with viral vectors. For
example, the H1 vaccine comprises a fusion protein of Ag85B-
ESAT6 in the adjuvant IC31, while others were delivered via DNA
or viral vectors, such as MVA85A and Ad5HUAG85A (Rappuoli
and Aderem, 2011; Knudsen et al., 2014).
One of the most popular antigens used to generate TB
vaccines is the TB antigen 85A (Ag85A). Ag85A comprises a
major fraction of the secreted proteins in M. tuberculosis and
Mycobacterium bovis BCG culture filtrate, and belongs to the
Ag85 complex, a 30- to 32-kDa family of three proteins (Ag85A,
Ag85B, and Ag85C; Wiker and Harboe, 1992; Belisle et al.,
1997), all of which exhibit mycolyltransferase activity. These
proteins are encoded by three paralogous genes located in distinct
regions of the bacterial genome (Content et al., 1991). Ag85A
can induce strong T-cell proliferation and IFN-γ production
in healthy individuals infected with M. tuberculosis and in M.
bovis BCG-vaccinated mice (D’Souza et al., 2003). Because this
antigen induces protective immune responses, it is among the
most promising candidates for use in future development of
tuberculosis vaccines. MVA85A is a modified vaccinia virus
Ankara (MVA): a live-attenuated poxvirus vector expressing
Ag85A. This virus induces strong CD4+ T cell responses in
animals and humans, and provides enhanced protection in
BCG-primed MVA85A-boosted animals challenged with M.
tuberculosis (Verreck et al., 2009). However, in a recent trial,
MVA85A was given to infants as a BCG booster, but the presence
of MVA85A protein did not protect against TB infection better
than the BCG immunization alone (Tameris et al., 2013; Harris
et al., 2014). Ad5HUAG85A is human Ad5 expressing Ag85A,
and the Ad induces CD8+T cell responses, but the pre-existing
antibodies may cause the elimination thus reducing the vaccine
efficacy (Kaufmann et al., 2014).
While adding MVA85A or Ad5HUAG85A as the booster
to the BCG vaccine exhibited no significant improvement in
vaccine efficacy, there is no doubt that the Ag85A antigen itself
is able to induce protection, so an approach via overexpressing
the tuberculosis antigen Ag85A in attenuated BCG strains may
have great promise in TB vaccine development. In this study,
we generated a recombinant BCG strain that overexpresses
the immunodominant Ag85A antigen, and evaluated its
immunogenicity and protective efficacy in mice challenged with
aerosolized M. tuberculosis, to assess its potential as a candidate
vaccine against TB.
MATERIALS AND METHODS
Experimental Animals
Six-week-old female C57BL/6 mice were purchased from VITAL
RIVER (Beijing, China). Mice were housed, handled, and
immunized at the animal biosafety facilities and all procedures
were approved by the institutional animal experimental
committee of Yangzhou University. All M. tuberculosis H37Rv
challenge experiments were performed in the Animal Biosafety
Level 3 (ABSL-3) facility of Wuhan University.
Bacterial Strains and Cell Culture
The Escherichia coli strain DH5α was used for cloning and
grown in Luria broth (LB). M. bovis BCG Pasteur 1173P2
and rBCG were grown in Middle brook 7H9 medium (Difco,
MI, USA) supplemented with 0.05% Tween 80 and 10% acid–
albumin–dextrose–catalase complex (ADC), or on solid Middle
brook 7H10 medium (Difco) supplemented with oleic acid–
albumin–dextrose–catalase complex (OADC). Kanamycin was
added when required (final concentration 25µg/ml). The Ag85A
epitope-specific (241–260) T cell hybridoma (DE10) was a gift
from Dr. Claude Leclerc (Institut Pasteur, Paris; Johansen et al.,
2011).
Construction of Recombinant BCG
The gene fragment, fbpA, was PCR amplified usingM. bovis BCG
Pasteur 1173P2 chromosomal DNA as a template. The forward
primer (5′-TA GGA TCC ATG CAG CTT GTT GAC AG-3′)
contained a BamHI restriction site and the reverse primer (5′-
TA GAA TTC GTT GTG TCT GTT CGG AGC-3′) contained an
EcoRI restriction site. The resulting 1050 bp fragment was ligated
to the T-cloning site of a pCR2.1 vector (Invitrogen, Carlsbad,
CA, USA), isolated by digestion with BamHI and EcoRI, and
ligated into the shuttle plasmid pMV261 to generate pMV261–
fbpA. The recombinant shuttle plasmid was transformed into a
wild type BCG strain by electroporation as described previously
(Wang et al., 2009). The BCG-transformed bacterial cells were
incubated on 7H10 solid media (supplemented with 25µg/ml
kanamycin) and grown at 37◦C for 2–3 weeks. Transformants
were selected and confirmed by PCR using forward (5′-GAG
GAA TCA CTT CGC AAT GG-3′) and reverse primers (5′-
GCC TTT CGT TTT ATT TGA TGC C-3′) that lie 5′ and 3′ of
pMV261 MCS.
Western Blot Analysis
BCG-positive transformants were grown in Middle brook 7H9
medium containing 25µg/ml of kanamycin. After 2–3 weeks,
protein expression was induced by incubating the cultures at
45◦C for 2 h. rBCG cells were centrifuged at 8000 rpm for
10min, and cell lysate was separated on a 12% SDS-PAGE gel.
Proteins were then transferred to a PVDF membrane, and the
membrane was blocked with 2% bovine serum albumin (BSA)
in phosphate buffered saline (PBS) at room temperature for
2 h. After blocking, the membrane was washed three times with
PBS containing 0.05% Tween 20 (PBST). The membrane was
then incubated with an anti-Ag85A monoclonal antibody (mAb)
6B5 (1:1000; preserved at Jiangsu Key Laboratory of Zoonosis)
at room temperature for 1 h. After three consecutive washes
with PBST, the membrane was incubated with a horseradish
peroxidase (HRP)-labeled goat anti-mouse secondary antibody
(1:2000; Sigma, St. Louis, MO, USA). Finally, the membrane
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was developed with 3,3′-diaminobenzidine tetrahydrochloride
(Sigma, USA) and visualized using X-ray film.
Indirect Enzyme-Linked Immunosorbent
Assays (ELISAs)
ELISA plates (Nunc, Denmark) were treated with 5%
glutaraldehyde (100µl/well) and incubated at 37◦C for 2 h.
The plates were washed three times with PBST, then coated with
1 × 106 colony-forming units (CFU) of BCG or rBCG::Ag85A
bacteria (100µl/well) overnight at 56◦C, after three washes with
PBST the plates were blocked with PBS containing 2% BSA at
37◦C for 2 h. The plates were washed threemore times with PBST,
and mAb 6B5 was added at two-fold serial dilutions (beginning
at a 1:100 dilution) and incubated at 37◦C for 2 h. HRP-labeled
goat anti-mouse IgG (1:8000 dilution; Sigma-Aldrich, USA) was
added to each well (100µl/well) and incubated at 37◦C for 1 h.
The TMB substrate was then added to the plates and incubated
for 10min, after which the plates were read at 450 nm.
Immunizations and Challenge
Groups of C57BL/6 mice (10 per group) were immunized
subcutaneously (s.c) with 5 × 106 CFUs of either BCG or
rBCG::Ag85A suspended in 100µl PBS. Unvaccinated mice,
which served as a control, received an equal volume of PBS. At
6 weeks post-vaccination, mice were challenged with aerosolized
M. tuberculosis H37Rv with Glas-Col chamber as described
previously (Zhang et al., 2011), during which time approximately
200 bacteria were deposited in the lungs of each animal.
Antigen Presentation Assays
C57/BL6 mice were injected subcutaneously with 5×106 CFU of
BCG or rBCG::Ag85A bacteria, and their draining lymph nodes
were removed at 0, 4, 24, and 48 h post-injection, respectively,
and perfused with 400 U/ml of collagenase type IV (Invitrogen)
containing 50µg/ml of DNase I (Invitrogen). Single-cell
suspensions were prepared from the isolated lymph nodes and
dendritic cells (DCs) were sorted with an autoMACS instrument
(MiltenyiBiotec, Germany) using anti-CD11c microbeads
(MiltenyiBiotec, Germany), leading to a CD11c+ positive cell
sample >90% purity. For the ex vivo antigen presentation assay,
1 × 105 isolated DCs were added to 96-well microplates, then
1 × 105 DE10 T cell hybridomas were added to the antigen
presenting cells, and incubated at 37◦C in a 5% CO2 atmosphere
for 24 h. The supernatants were harvested, frozen and tested for
IL-2 production using a sandwich ELISA (BD Biosciences, USA).
Cytokine Production
BCG and rBCG::Ag85A-vaccinated mice were sacrificed 6 weeks
post-immunization, and their spleens and draining lymph nodes
were removed aseptically in RPMI-1640 medium supplemented
with 10% fetal calf serum, 100 g/ml streptomycin, and 100
IU/ml penicillin. The single-cell suspensions were prepared using
Histopaque 1083 (Sigma, USA), and then the cells were added
to 96-well plates containing RPMI-1640 medium (1 × 106
cells/well in 200µl media). Cells were stimulated with 10µg/ml
of Ag85A peptide, 10µg/ml of Ag85A protein, or 5µg/ml of
bovine purified protein derivative (PPD, Prionics, Switzerland).
The cells were incubated at 37◦C in a 5% CO2 atmosphere, and
the supernatants were harvested 48 h post-stimulation, frozen,
and tested for IFN-γ and IL-4 production by sandwich ELISA
(BD Biosciences, USA).
Ag85A-Specific IgG ELISA Assays
C57BL/6 mouse sera were collected from the various groups of
mice for antibody detection. ELISA plates (Nunc) were coated
with Ag85A (5µg/ml, 100µl/well) overnight at 4◦C. The plates
were washed three times with PBST, and blocked with 2% BSA
in PBS for 2 h at 37◦C. Samples were washed three additional
times, and treated with serum samples at two-fold serial dilutions
(beginning at 1:500 dilution) for 2 h at 37◦C. HRP-labeled goat
anti-mouse IgG (Sigma-Aldrich), HRP-labeled goat anti-mouse
IgG1 (Invitrogen), and HRP-labeled goat anti-mouse IgG2b
(Southern Biotec, Birmingham, AL, USA) were used at 1:8000
dilutions; 100µl of the serially diluted antibodies were added
individually to the wells of each plate, and the plates were
incubated at 37◦C for 1 h. The substrate TMB was added and
incubated for 10min, and the plates were read at 450 nm.
CFU Measurements
Mice were sacrificed 6 weeks post M. tuberculosis challenge,
and their lungs and spleens were removed aseptically. For
enumeration of actual CFU, a portion of spleens and lungs
was weighed and homogenized, and the bacterial load was
determined by plating 10-fold dilutions of the tissue homogenate
on 7H10Middle brook agar plates. Plates were incubated at 37◦C
for at least 3 weeks, and colonies were counted and expressed as
log10 CFU per organ.
Histopathological Analysis
For histopathological study, lung and spleen tissues were
fixed in 10% formalin and embedded in paraffin. Sections
measuring approximately 4–6µm were prepared and used for
acid-fast staining and hematoxylin and eosin (HE) staining.
Histopathological evaluation and scoring were performed by a
single pathologist unaware of the treatment groups for at least
twice to verify the reproducibility of the observations.
Statistical Analysis
All data are expressed as mean ± SEM. Statistical analysis was
performed using a Student’s t-test. A value of P < 0.05 was
considered statistically significant.
RESULTS
Construction and Isolation of rBCG::Ag85A
Bacteria
The gene encoding Ag85A was amplified (Figure S1A) and
cloned into the E. coli–M. tuberculosis shuttle vector, pMV261.
The recombinant vector pMV261–fbpA (Figure S1B) was
confirmed by sequencing, then transformed into the BCGPasteur
1173P2 strain. Candidate rBCG::Ag85A clones were isolated and
verified by PCR amplification, confirming that the recombinant
vector pMV261–fbpA had been successfully transformed into the
rBCG::Ag85A strain (Figure S1C).
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 3 January 2016 | Volume 6 | Article 3
Xu et al. Recombinant BCG Overexpressing Ag85A
FIGURE 1 | Confirmation of Ag85A expression by Western blot
analysis. Western blot analysis of the 31 kDa Ag85A in BCG (A) and
rBCG::Ag85A (B). Ag85A protein levels increased two-fold in rBCG::Ag85A.
Quantitative analyses of the protein bands were performed using Image J
Software (National Institutes of Health, Maryland, USA).
Confirmation of Ag85A Overexpression by
Western Blot Analysis
Overexpression of the Ag85A protein in the rBCG::Ag85A strain
was confirmed by western blotting using the anti-Ag85A mAb,
6B5. The untransformed BCG strain was used as a control. The
results demonstrate that the 31 kDa Ag85A protein levels are
increased two-fold in rBCG::Ag85A compared with those of BCG
(Figure 1), while the 30 and 31.5 kDa proteins represent Ag85B
and Ag85C, respectively.
Evaluation of Ag85A Expression by Indirect
ELISA
To confirm the overexpression of Ag85A in rBCG::Ag85A,
plates coated with equal amounts of BCG and rBCG::Ag85A
bacteria were used to assess Ag85A expression by indirect ELISA
using serially diluted 6B5mAb. The optical density (OD) of
rBCG Ag85A was significantly higher than that of BCG Ag85A
(Figure 2), confirming that the Ag85A protein was successfully
overexpressed in rBCG::Ag85A.
Antigen Presenting Assays
Next, we investigated the antigen-presenting activity of the
cells ex vivo by harvesting the draining lymph nodes from
rBCG::Ag85A and BCG infected mice. After s.c. administration
of rBCG::Ag85A, we isolated DCs from the lymph nodes and
monitored their capacity to stimulate the DE10 T hybridoma,
FIGURE 2 | Identification of Ag85A expression by indirect ELISA. An
ELISA plate coated with equal amounts of BCG and rBCG::Ag85A bacteria
was probed for Ag85A expression with serially diluted mAb 6B5. Expression of
Ag85A by rBCG::Ag85A was significantly higher than that by BCG. Data
depicted are the mean values ± SEM. Statistical significance was determined
by a Student’s t-test.
FIGURE 3 | Ex vivo detection of antigen-presentation following
rBCG::Ag85A infection. After s.c. administration of rBCG::Ag85A, DCs from
mouse lymph nodes were analyzed for their ability to stimulate the DE10 T
hybridoma by probing for Ag85A peptide presentation in MHC complexes.
Ag85A-M was detected 4 h post-rBCG infection. rBCG::Ag85A induced
higher levels of Ag85A-specific antigen-presenting activity in mice compared
with those immunized with BCG. Data depicted are the mean values ± SEM.
Statistical significance was determined by a Student’s t-test (*P < 0.05,
**P < 0.01).
which is specific for a dominant Ag85A peptide. Under these
conditions, the in vivo formation of Ag85A peptide–MHC
complexes on DCs from BCG-infected mice was detected ex
vivo by T cell hybridoma stimulation. Ag85A peptide–MHC
complexes on the isolated DCs were detected as early as
4 h post rBCG::Ag85A immunization (Figure 3). rBCG::Ag85A
immunization also induced a higher level of Ag85A-specific
antigen-presenting activity than BCG alone.
Cytokine Responses
To evaluate the T cell immune responses primed by
immunization with rBCG::Ag85A and BCG bacteria, we
monitored IFN-γ cytokine levels in the culture supernatants
of lymphocytes stimulated with either Ag85A peptide, purified
Ag85A protein, or PPD antigens by ELISA. Lymphocytes from
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the draining lymph nodes and spleens from the PBS control
group produced very low IFN-γ levels. The highest levels of
IFN-γ production were observed in culture supernatants of
lymphocytes derived from rBCG::Ag85A-immunized mice
(Figure 4). In contrast, IL-4 production by all samples was below
the detection limits of the assay (data not show). These results
indicate that rBCG::Ag85A can enhance Th1 cytokine secretion.
Antigen-Specific Humoral Responses
The specific antibody responses induced by BCG and
rBCG::Ag85A strains were evaluated by ELISA, and IgG,
IgG1, and IgG2b titers were calculated for the sera of mice
sacrificed 4 weeks post-immunization. Mice immunized with
rBCG::Ag85A exhibited higher levels of Ag85A-specific IgG
than those immunized with BCG (Figure 5A), suggesting that
rBCG::Ag85A induced a more efficient humoral response in
mice than that induced by BCG alone. Furthermore, we analyzed
titers of IgG1 and IgG2b, and found that the titers of IgG2b in the
sera of rBCG::Ag85A-immunized mice were higher than IgG1
(Figure 5B). These results indicate that rBCG::Ag85A induced
strong humoral and Th1 immune responses in the C57BL/ 6
mice.
Determination of Bacterial Loads
To determine the immune-protective efficacy of the
rBCG::Ag85A strain, C57BL/6 mice immunized with
rBCG::Ag85A or BCG were challenged with M. tuberculosis. 6
weeks post challenge, mice were sacrificed and bacterial load in
the lung and spleen of each mouse was analyzed. TB challenge
led to the highest bacterial load in the lung and spleen in the PBS
control (Figure 6). Vaccination with BCG and rBCG::Ag85A
strains strongly reduced bacterial load in the lung and spleen
in C57BL/6 mice. rBCG::Ag85A inhibited the growth of M.
tuberculosis significantly in the lung and spleen compared
with PBS group, however, rBCG::Ag85A resulted in higher but
not significant decrease of bacterial load compared to BCG
vaccinated C57BL/6 mice. These results were confirmed by
acid-fast staining histology, which showed that the number of
bacteria in the lung and spleen from the group immunized with
rBCG::Ag85A was lower than other groups (Figure 7).
Evaluation of Pathological Changes
To evaluate pathological changes in immunized mice, lung,
and spleen tissues from different groups of C57BL/6 mice were
fixed, sectioned, and stained with HE stain for assessment of
pathological changes. Six weeks after challenge with TB, the most
serious pathological changes occurred in the lungs of the mice
from the PBS control group, which exhibited the largest number
of granuloma-like nodes (Figure 8). Comparatively, pathological
changes were less severe in the lung tissue from mice vaccinated
with BCG and rBCG::Ag85A, and damage to the lung tissue of
rBCG::Ag85A immunized mice was less advanced than in the
BCG immunized group. The results of the lung histopathology
suggest that rBCG::Ag85A is more effective at protecting lung
tissue from damage caused by M. tuberculosis infection than
BCG. No obvious pathological changes were observed in the
spleen tissue of mice in any treatment group.
DISCUSSION
M. bovis BCG is currently the only vaccine available against TB,
but it does not prevent the development of pulmonary TB in
adults (Fine, 1995; Andersen and Doherty, 2005). As a result,
new strategies are needed to improve the effectiveness of the
current TB vaccine. As vaccine components, the Ag85 complex
proteins have been extensively explored, it has been shown that
rBCG overexpressing Ag85B enhanced the immunogenicity of
BCG and induced a robust and long-lasting immune response
(Xu et al., 2007; Wang et al., 2009; Shen et al., 2010).
In the present study, we constructed a recombinant BCG
strain overexpressing the immunodominant Ag85A antigen and
evaluated its immunogenicity and protective efficacy.
It has been confirmed that antigens expressed, secreted, or
linked to the cell membrane by BCG can influence the timing
of immune responses and the pathways by which antigen is
presented to immune cells (Dennehy and Williamson, 2005).
The presentation pathways, for example, via the MHC class
II pathway, will determine the cellular and humoral immune
responses induced by rBCG. In this study, we explored the
antigen presenting kinetics of a recombinant BCG strain
overexpressing the immunodominant antigen Ag85A in mice.
The Ag85A peptide and MHC complexes were detected on
draining lymph node DCs from BCG-infected mice 4 h post-
infection with rBCG, and rBCG::Ag85A induced higher levels of
Ag85A-specific antigen-presenting activity than those observed
for BCG.
CD4+ T cells and IFN-γ responses are important components
of immune responses against M. tuberculosis, and the CD4+ T
cell response is important in controllingM. tuberculosis infection
and preventing or delaying the onset of disease (Flynn et al.,
1993; Flynn, 2004). We predicted that BCG bacteria producing
Ag85A would stimulate IFN-γ production in TB challenged
mice better than BCG alone. Lymphocytes isolated from BCG-
and rBCG::Ag85A-immunized mice exhibited increased IFN-γ
secretion, while mock-immunized mice showed only a slight
IFN-γ response. Further, IFN-γ production by lymphocytes
from rBCG::Ag85A-immunized mice was significantly
higher than in BCG-immunized mice, suggesting that
rBCG::Ag85A may induce stronger cellular responses than BCG
in mice.
The production of immunoglobulins able to recognize
TB epitopes is essential for immune surveillance and rapid
response to infection. To determine whether the rBCG::Ag85A
strain increases antibody production, antibody titers in
the rBCG::Ag85A-immunized mice and BCG-immunized
mice were assessed. rBCG::Ag85A immunization generated
significantly higher IgG antibody titers than those of the BCG
strain, indicating that rBCG::Ag85A stimulates more robust
immunoglobulin production than BCG. In mice, the IgG2b
antibody response is associated with a Th1-type immune
response, whereas the Th2 cytokine response is characterized
by IgG1 and IgE antibody responses (Mosmann and Coffman,
1989). The levels of Ag85A-specific IgG1 and IgG2b were
examined in the sera of mice infected with rBCG::Ag85A or
BCG. IgG2b titer was found to be significantly higher than IgG1
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FIGURE 4 | Antigen-specific cellular immune responses following rBCG::Ag85A infection. IFN-γ levels in culture supernatants of lymphocytes stimulated
in vitro with either culture medium (CM), Ag85A peptide, purified Ag85A protein, or PPD were detected by sandwich ELISA. Lymphocytes from draining lymph nodes
(left) or spleens (right) from the PBS control group produced very low levels of IFN-γ; higher levels of IFN-γ were found in the rBCG::Ag85A-immunized mice compared
with those of the BCG-immunized mice. Data depicted represent the mean values ± SEM. Statistical significance was determined by a Student’s t-test (*P < 0.05).
FIGURE 5 | Antigen-specific antibody responses following immunization with rBCG::Ag85A. Mice immunized with rBCG::Ag85A had higher levels of
Ag85A-specific IgG than those immunized with BCG (A). The IgG2b to IgG1 ratio in the sera of mice immunized with rBCG::Ag85A was higher than that of BCG (B).
Data depicted represent the mean values ± SEM. Statistical significance was determined by a Student’s t-test (*P < 0.05).
FIGURE 6 | Bacterial load in the lung and spleen of immunized, TB challenged mice. Four weeks post-immunization, C57BL/6 mice (n = 6) were challenged
with 5× 106 CFU aerosolized virulent M. tuberculosis (strain H37Rv). Six weeks after TB challenge, spleens and lungs were harvested and the numbers of CFU per
organ were enumerated. TB challenge led to the highest bacterial load in the lung (A) and spleen (B) in the PBS control. Vaccination with BCG and rBCG::Ag85A
strains strongly reduced bacterial load in the lung and spleen in C57BL/6 mice. Data depicted are the mean values ± SEM. Statistical significance was determined by
a Student’s t-test (**P < 0.01, ***P < 0.001).
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FIGURE 7 | Histology of the lung and spleen in TB-challenged mice. Vaccinated C57BL/6 mice were challenged by aerosol with 5× 106 CFU virulent M.
tuberculosis H37Rv strain. Six weeks after infection, lung (A–C,G) and spleen (D–F,H) tissue sections from PBS group (A,D), BCG group (B,E), and rBCG::Ag85A
group (C,F) were prepared for acid-fast staining (×4). The number of bacteria in the lung and spleen from the group immunized with rBCG::Ag85A (C,F) was lower
than PBS group (A,D) and BCG group (B,E). Vaccination with BCG and rBCG::Ag85A strains strongly reduced bacterial load in the lung and spleen in C57BL/6 mice
(G,H). Data depicted are the mean values ± SEM. Statistical significance was determined by a Student’s t-test (**P < 0.01).
in the rBCG::Ag85A-infectedmice, suggesting that rBCG::Ag85A
may produce stronger Th1 responses than BCG in mice.
Previous experiments using recombinant BCG strains
demonstrated that the insertion of genes encoding
immunodominant antigens such as Ag85B, MPT64, ESAT-
6, or PPE protein (Xu et al., 2007; Qie et al., 2009; Wang et al.,
2009) and immunoregulatory cytokines such as IL-2, IFN-γ, and
TNF-α (Murray et al., 1996; Wangoo et al., 2000; Shen et al.,
2010) provided more protective efficacy than the parent BCG
vaccine. Our recombinant BCG strain rBCG::Ag85A exhibited
similar effects: bacterial load in the lung and spleen after TB
challenge was decreased by inoculation with rBCG::Ag85A and
BCG, and rBCG::Ag85A resulted in a slightly enhanced, although
not significant, decrease of bacterial load compared to the BCG
vaccination. Results of acid-fast staining of lung tissue from
each treatment group showed that the most serious pathological
changes of lung occurred in PBS control group, while the
rBCG::Ag85A group exhibited the least tissue damage among all
groups. These results suggest that the ability of rBCG::Ag85A
may be more effective at preventing tissue damage caused by M.
tuberculosis infection than BCG.
In our immunization experiments, the bacterial loads and
pathological changes were all less in the mice immunized
with rBCG::Ag85A compared with those induced by BCG
immunization, however, the protective efficacy of rBCG::Ag85A
was not significantly higher than the parental BCG. As a result,
more research is needed to further enhance the expression
of recombinant Ag85A protein in rBCG, and to optimize
immunization methods and dose administration.
In summary, we have constructed a recombinant BCG
strain overexpressing the immunodominant antigen Ag85A
and evaluated its immunogenicity and protective efficacy in
mice. Our results demonstrate that rBCG::Ag85A improves the
immunogenicity of BCG, and induces significantly enhanced
cellular and humoral immune responses in mice. Although not
statistically significant, mice immunized with the rBCG::Ag85A
strain are slightly better protected againstM. tuberculosis H37Rv
infection compared with the BCG vaccine, thus demonstrating
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FIGURE 8 | Representative lung and spleen pathology of C57BL/6 mice after challenge. Vaccinated C57BL/6 mice were challenged by aerosol with 5× 106
CFU virulent M. tuberculosis H37Rv strain. Six weeks after infection, lung (A–F) and spleen (G–L) tissue sections from PBS groups (A,D,G,J), BCG group (B,E,H,K),
and rBCG::Ag85A group (C,F,I,L) were prepared for HE staining (×160). The most serious pathological changes occurred in the lung of the mice from the PBS control
group (A,D), which exhibited the largest number of granuloma-like nodes. Comparatively, pathological changes were less severe in the lung tissue from mice
vaccinated with BCG and rBCG::Ag85A (B,C,E,F). No obvious pathological changes were observed in the spleen tissue of mice in any treatment group (G–L). Data
depicted are the mean values ± SEM. Statistical significance was determined by a Student’s t-test (**P < 0.01).
its therapeutic potential as a vaccine against TB. However, further
improvement and evaluation of recombinant BCG are necessary.
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